Browse by author
Lookup NU author(s): Dr Daniel Erskine,
Professor John-Paul Taylor
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Cholinergic dysfunction is involved in a range of neurological and psychiatric disorders, including schizophrenia, dementia and Lewy body disease (LBD), leading to widespread use of cholinergic therapies. However, such drugs have focussed on increasing the availability of acetylcholine (ACh) generally, with relatively little work done on the muscarinic system and specific muscarinic receptor subtypes. In this review, we provide an overview of the major cholinergic pathways and cholinergic muscarinic receptors in the human brain and evidence for their dysfunction in several neurological and psychiatric disorders. We discuss how the selectivity of cholinergic system dysfunction suggests that targeted cholinergic therapeutics to the muscarinic receptor subtypes will be vital in treating several disorders associated with cognitive dysfunction and behavioural and psychological symptoms.
Author(s): Erskine D, Taylor JP, Bakker G, Brown AJH, Tasker T, Nathan PJ
Publication type: Article
Publication status: Published
Journal: Drug Discovery Today
Print publication date: 01/12/2019
Online publication date: 06/09/2019
Acceptance date: 06/09/2019
ISSN (print): 1359-6446
ISSN (electronic): 1878-5832
PubMed id: 31499186
Altmetrics provided by Altmetric